Clinical Trial

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-31.
Trial Details
NCT Number NCT07516093
Lead Sponsor Nurix Therapeutics, Inc.
Conditions B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 620 participants
Start Date 2026-06
Primary Completion 2029-10 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-08